Carla Gambarana

Prof. Carla Gambarana

University of Siena, Siena, Tuscany, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2018 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
Simona ScheggiSimona Scheggi
Simona Scheggi
MMMaria Graziella De Montis
Maria Graziella De Montis
CGCarla Gambarana
Carla Gambarana
A markedly reduced interest or pleasure in activities previously considered pleasurable is a main symptom in mood disorder and psychosis and is often present in other psychiatric disorders and neurodegenerative diseases. This condition can be labeled as “anhedonia,” although in its most rigorous connotation the term refers to the lost capacity to feel pleasure that is one aspect of the complex phenomenon of processing and responding to reward. The responses to rewarding stimuli are relatively easy to study in rodents, and the experimental conditions that consistently and persistently impair these responses are used to model anhedonia. To this end, long-term exposure to environmental aversive conditions is primarily used, and the resulting deficits in reward responses are often accompanied by other deficits that are mainly reminiscent of clinical depressive symptoms. The different components of impaired reward responses induced by environmental aversive events can be assessed by different tests or protocols that require different degrees of time allocation, technical resources, and equipment. Rodent models of anhedonia are valuable tools in the study of the neurobiological mechanisms underpinning impaired behavioral responses and in the screening and characterization of drugs that may reverse these behavioral deficits. In particular, the antianhedonic or promotivational effects are relevant features in the spectrum of activities of drugs used in mood disorders or psychosis. Thus, more than the model, it is the choice of tests that is crucial since it influences which facets of anhedonia will be detected and should be tuned to the purpose of the study.

25 July 2018 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Simona ScheggiSimona Scheggi
Simona Scheggi
MMMaria Graziella De Montis
Maria Graziella De Montis
CGCarla Gambarana
Carla Gambarana
Dopamine‐ and cAMP‐regulated phosphoprotein (Mr 32 kDa, DARPP‐32) is an integrator of multiple neuronal signals and plays a crucial role particularly in mediating the dopaminergic component of the systems involved in the evaluation of stimuli and the ensuing elaboration of complex behavioral responses (e.g., responses to reinforcers and stressors). Dopamine neurons can fire tonically or phasically in distinct timescales and in specific brain regions to code different behaviorally relevant information. Dopamine signaling is mediated mainly through the regulation of adenylyl cyclase activity, stimulated by D1‐like or inhibited by D2‐like receptors, respectively, that modulates cAMP‐dependent protein kinase (PKA) function. The activity of DARPP‐32 is finely regulated by its phosphorylation at multiple sites. Phosphorylation at the threonine (Thr) 34 residue by PKA converts DARPP‐32 into an inhibitor of protein phosphatase 1, while the phosphorylation at the Thr75 residue turns it into an inhibitor of PKA. Thus, DARPP‐32 is critically implicated in regulating striatal output in response to the convergent pathways that influence signaling of the cAMP/PKA pathway. This review summarizes some of the landmark and recent studies of DARPP‐32‐mediated signaling in the attempt to clarify the role played by DARPP‐32 in the response to rewarding natural stimuli. Particularly, the review deals with data derived from rodents studies and discusses the involvement of the cAMP/PKA/DARPP‐32 pathway in: 1) appetitive food‐sustained motivated behaviors, 2) motivated behaviors sustained by social reward, 3) sexual behavior, and 4) responses to environmental enrichment. image

20 May 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Simona ScheggiSimona Scheggi
Simona Scheggi
Graziano PinnaGraziano Pinna
Graziano Pinna
Giulia BraccagniGiulia Braccagni
Giulia Braccagni
MMMaria Graziella De Montis
Maria Graziella De Montis
CGCarla Gambarana
Carla Gambarana
Peroxisome proliferator-activator receptors (PPARs) regulate lipid and glucose metabolism, control inflammatory processes, and modulate several brain functions. Three PPAR isoforms have been identified, PPARα, PPARβ/δ, and PPARγ, which are expressed in different tissues and cell types. Hereinafter, we focus on PPARα involvement in the pathophysiology of neuropsychiatric and neurodegenerative disorders, which is underscored by PPARα localization in neuronal circuits involved in emotion modulation and stress response, and its role in neurodevelopment and neuroinflammation. A multiplicity of downstream pathways modulated by PPARα activation, including glutamatergic neurotransmission, upregulation of brain-derived neurotrophic factor, and neurosteroidogenic effects, encompass mechanisms underlying behavioral regulation. Modulation of dopamine neuronal firing in the ventral tegmental area likely contributes to PPARα effects in depression, anhedonia, and autism spectrum disorder (ASD). Based on robust preclinical evidence and the initial results of clinical studies, future clinical trials should assess the efficacy of PPARα agonists in the treatment of mood and neurodevelopmental disorders, such as depression, schizophrenia, and ASD.


2 January 2012 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
FGFederica Gambelli
Federica Gambelli
FSFederica Sasdelli
Federica Sasdelli
IMIvana Manini
Ivana Manini
CGCarla Gambarana
Carla Gambarana
GOGiuseppe Oliveri
Giuseppe Oliveri
Vincenzo SorrentinoVincenzo Sorrentino
Vincenzo Sorrentino

1 August 2013 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
GMGiovanna Marchese
Giovanna Marchese
Simona ScheggiSimona Scheggi
Simona Scheggi
MSMaria Elena Secci
Maria Elena Secci
MMMaria Graziella De Montis
Maria Graziella De Montis
CGCarla Gambarana
Carla Gambarana
Behavioural and neurochemical responses to palatable food exposure represent an index of hedonic competence. In rats, a palatable meal increases extra-neuronal dopamine levels in the nucleus accumbens shell (NAcS) that confers to it incentive salience and reinforcing value. Repeated stress exposure decreases dopamine output and impairs the NAcS dopaminergic response to palatable food and the competence to acquire a vanilla sugar (VS)-reinforced instrumental behaviour [VS-sustained appetitive behaviour (VAB)]. Moreover, chronic stress exposure disrupts reactivity to aversive stimuli. A 3-wk treatment with lithium, the gold-standard treatment in bipolar disorder, tonically reduces NAcS dopamine output and the reactivity to aversive stimuli. However, it does not affect the dopaminergic response to VS and the competence to acquire VAB. This study investigated whether repeated lithium administration is endowed with anti-anhedonic activity. The NAcS dopaminergic response to VS and the competence to acquire VAB and sucrose self-administration (SA), in terms of fixed-ratio (FR)1, FR5 and progressive ratio schedules of reinforcement, were studied in saline or lithium-treated groups of non-food-deprived rats exposed or not to repeated unavoidable stress. Chronic stress exposure impaired the NAcS dopaminergic response to VS, acquisition of VAB and sucrose SA, in terms of FR1 and FR5 schedules of reinforcement and breaking point score. Repeated lithium treatment restored these parameters to control group values, even when treatment began in rats already showing an anhedonia-like condition. Since the breaking point defines the reinforcement efficacy of a hedonic stimulus, the present data suggest that lithium treatment is endowed with anti-anhedonic activity in rats.